Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Granisetron transdermal - Kyowa Kirin International

Next Previous
Drug Profile

Granisetron transdermal - Kyowa Kirin International

Alternative Names: Sancuso; SP 01; SP-01 - Solasia Pharma

Latest Information Update: 27 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProStrakan
  • Developer Kyowa Kirin; Kyowa Kirin International; LG Chem; NewBridge Pharmaceuticals; Solasia Pharma
  • Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 25 Feb 2023 Cumberland Pharmaceuticals terminates national co-promotion agreement with Verity Pharmaceuticals to support granisetron transdermal in the US
  • 09 May 2022 Cumberland Pharmaceuticals and Verity Pharmaceuticals agree to co-promote Granisetron transdermal in USA for Chemotherapy-induced nausea and vomiting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top